As a simplified single-gene example from our dataset, since NEK2 is upregulated in many cancers [76], we propose this may be one biomarker within a biomarker panel which, when overexpressed, may be predictive of patients who fail HCQ-based therapies. This evidence concerns the gene NEK2 and cancer.